JP4094679B2 - Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用 - Google Patents

Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用 Download PDF

Info

Publication number
JP4094679B2
JP4094679B2 JP53885498A JP53885498A JP4094679B2 JP 4094679 B2 JP4094679 B2 JP 4094679B2 JP 53885498 A JP53885498 A JP 53885498A JP 53885498 A JP53885498 A JP 53885498A JP 4094679 B2 JP4094679 B2 JP 4094679B2
Authority
JP
Japan
Prior art keywords
hcv
rna
sequence
replication
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53885498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515353A (ja
JP2001515353A5 (https=
Inventor
エム サード ライス，チャールズ
エイ コリハロフ，アレキサンダー
Original Assignee
ワシントン ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワシントン ユニヴァーシティ filed Critical ワシントン ユニヴァーシティ
Publication of JP2001515353A publication Critical patent/JP2001515353A/ja
Publication of JP2001515353A5 publication Critical patent/JP2001515353A5/ja
Application granted granted Critical
Publication of JP4094679B2 publication Critical patent/JP4094679B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP53885498A 1997-03-04 1998-02-26 Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用 Expired - Lifetime JP4094679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/811,566 US6127116A (en) 1995-08-29 1997-03-04 Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US08/811,566 1997-03-04
PCT/US1998/004428 WO1998039031A1 (en) 1997-03-04 1998-02-26 Functional dna clone for hepatitis c virus (hcv) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007339488A Division JP4223068B2 (ja) 1997-03-04 2007-12-28 Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用

Publications (3)

Publication Number Publication Date
JP2001515353A JP2001515353A (ja) 2001-09-18
JP2001515353A5 JP2001515353A5 (https=) 2007-05-10
JP4094679B2 true JP4094679B2 (ja) 2008-06-04

Family

ID=25206905

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53885498A Expired - Lifetime JP4094679B2 (ja) 1997-03-04 1998-02-26 Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用
JP2007339488A Expired - Lifetime JP4223068B2 (ja) 1997-03-04 2007-12-28 Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007339488A Expired - Lifetime JP4223068B2 (ja) 1997-03-04 2007-12-28 Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用

Country Status (9)

Country Link
US (4) US6127116A (https=)
EP (1) EP1005366A4 (https=)
JP (2) JP4094679B2 (https=)
AU (1) AU742175B2 (https=)
BR (1) BR9808147A (https=)
CA (1) CA2283464C (https=)
IL (2) IL131688A0 (https=)
WO (1) WO1998039031A1 (https=)
ZA (1) ZA981838B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
ATE395930T1 (de) * 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
DE19953854C2 (de) * 1999-11-09 2002-01-17 Max Planck Gesellschaft Verfahren zur Herstellung von Biopolymeren mit veränderten Eigenschaften
CA2392218A1 (en) * 1999-11-17 2001-05-25 Jiuping Ji Simultaneous detection of hbv, hcv and hiv in plasma samples using a multiplex capture assay
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
AU2001254563A1 (en) * 2000-04-21 2001-11-12 Boehringer Ingelheim (Canada) Ltd. Internal de novo initiation sites of the hcv ns5b polymerase and use thereof
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6447994B1 (en) * 2000-06-20 2002-09-10 The General Hospital Corporation Production of replicative hepatitis C virus
EP1327687A4 (en) * 2000-10-03 2004-08-11 Tokyo Metropolitan Org Med Res METHOD FOR INFECTING THE HEPATITIS C VIRUS
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
AU2002218906B2 (en) 2000-12-22 2006-08-03 Boehringer Ingelheim (Canada) Ltd. Self-replicating RNA molecule from hepatitis C virus
EP1381673B1 (en) * 2001-03-27 2009-05-13 Vertex Pharmaceuticals Incorporated Compositions and methods useful for hcv infection
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
WO2002090572A2 (en) * 2001-05-09 2002-11-14 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
WO2003040356A1 (en) * 2001-08-06 2003-05-15 Yangling Daiying Biological Engineering Co., Ltd The intact hepatitis c virus and the method for culturing it in a vitro cell culture
CA2461380C (en) * 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
US6689559B2 (en) * 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds
ES2346717T3 (es) * 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
KR100471946B1 (ko) * 2002-05-08 2005-03-08 (주)팬바이오넷 Ｃ형 간염바이러스(ｈｃｖ)의 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 탐지방법
WO2004005524A1 (en) * 2002-07-02 2004-01-15 Merck & Co., Inc. Hepatitis c virus particle formation
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
CA2868618C (en) * 2002-10-16 2017-05-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP2006506074A (ja) * 2002-11-13 2006-02-23 ワシントン ユニヴァーシティー Ｃ型肝炎ウイルスの複製に対して高許容性である細胞系
WO2005054450A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Compositions comprising fetal liver cells and methods useful for hcv infection
EP2423216B1 (en) 2003-12-01 2015-07-08 Board Of Regents, The University Of Texas System Replication competent hepatitis C virus and methods of use
ATE491810T1 (de) * 2004-01-23 2011-01-15 Bio Merieux Inc Neuartiges nukleotidgemisch für eine verbesserte nukleinsäurenamplifikationsleistung
US8099262B2 (en) 2004-03-02 2012-01-17 Virco Bvba Estimation of clinical cut-offs
AU2005222084B2 (en) 2004-03-05 2010-04-22 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of RNAI agents
US7833987B2 (en) * 2004-03-12 2010-11-16 Indian Institute Of Science Small synthetic RNA, a method of preparing the same and uses thereof
EP1792181B1 (en) * 2004-06-21 2010-11-17 Progenra Inc. Diagnostic and screening methods and kits associated with proteolytic activity
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
ATE474587T1 (de) * 2004-09-29 2010-08-15 Univ Tulane Inhibitoren des hepatitis-c-virus
CA2597655A1 (en) * 2005-02-16 2006-08-24 The Council Of The Queensland Institute Of Medical Research Flavivirus replicon constructs for tumour therapy
AU2006220887B2 (en) * 2005-03-04 2010-11-04 The Rockefeller University Infectious, chimeric Hepatitis C Virus, methods of producing the same and methods of use thereof
US20060234348A1 (en) * 2005-04-13 2006-10-19 Bujarski Jozef J Method of production of RNA polymerase protein
JP2007312649A (ja) * 2006-05-24 2007-12-06 Japan Health Science Foundation 再構築された感染性レトロウイルスゲノムクローンｄｎａ及びそれを含む微生物ならびにそれらの製造方法
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US7504255B2 (en) * 2006-08-17 2009-03-17 Saint Louis University Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
JP5627464B2 (ja) * 2007-11-26 2014-11-19 ノバルティス アーゲー アルファウイルス粒子を生成する方法
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US8829174B2 (en) 2008-10-29 2014-09-09 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
US20100129902A1 (en) 2008-11-24 2010-05-27 Erhard Ralf Schoenbrunner Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
US8609403B2 (en) * 2009-08-28 2013-12-17 Tokyo Metropolitan Institute Of Medical Science Polynucleotide derived from novel hepatitis C virus strain and use thereof
US20110070199A1 (en) * 2009-09-21 2011-03-24 Scheiber Ii Lane Bernard Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases
CN103649316B (zh) 2011-05-02 2017-07-28 约翰霍普金斯大学 合成的丙型肝炎基因组和制备及使用方法
EP2744894A4 (en) * 2011-08-18 2015-04-22 Ycine Llc PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST
CA2962696A1 (en) 2014-10-01 2016-04-07 National Research Council Of Canada Animal models, cell lines and methods for screening hepatitis c virus vaccines

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5218099A (en) * 1986-04-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Post-transfusion, non-A, non-B hepatitis virus polynucleotides
ES2061500T5 (es) * 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US5656731A (en) * 1987-10-15 1997-08-12 Chiron Corporation Nucleic acid-amplified immunoassay probes
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5312737A (en) * 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
US5176994A (en) * 1988-12-21 1993-01-05 Immuno Japan Inc. Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
EP0414475B1 (en) * 1989-08-25 1997-12-10 Chiron Corporation Methods for culturing HCV in B- or T-lymphocyte cell lines
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
ATE270326T1 (de) * 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
CA2079912C (en) * 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
WO1992000328A1 (en) * 1990-06-30 1992-01-09 Akzo N.V. Non-a non-b sequences
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
EP0842947B2 (en) * 1990-11-08 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Hepatitis C virus asialoglycoproteins
US5654179A (en) * 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
JPH06508024A (ja) * 1991-06-10 1994-09-14 ラッキー・リミテッド Ｃ型肝炎診断試薬およびワクチン
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
CA2116543C (en) * 1991-07-31 2007-10-02 Kay S. Greisen Methods and reagents for detection of bacteria in cerebrospinal fluid
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
ATE161291T1 (de) * 1991-08-27 1998-01-15 Hoffmann La Roche Verfahren und reagenzien zum nachweis von hepatitis c
US5427909A (en) * 1991-09-09 1995-06-27 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
EP0627000B1 (en) * 1992-01-31 2003-10-29 Abbott Laboratories Mammalian expression systems for hcv proteins
JPH06105690A (ja) * 1992-03-10 1994-04-19 Kunitada Shimotoono 血液伝播性非ａ非ｂ型肝炎ウィルスｄｎａ
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5552310A (en) * 1992-06-12 1996-09-03 Hiroshi Yoshikura Replication of hepatitis C virus genome and identification of virus having high infectivity
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
JPH06153961A (ja) * 1992-11-27 1994-06-03 Imuno Japan:Kk Ｃ型肝炎ウイルス部分遺伝子、ならびにｃ型肝炎ウイルス遺 伝子の高感度検出法
AU6364094A (en) * 1993-03-12 1994-09-26 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
TW275068B (https=) * 1993-09-24 1996-05-01 American Cyanamid Co
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof

Also Published As

Publication number Publication date
CA2283464A1 (en) 1998-09-11
BR9808147A (pt) 2000-03-28
US6127116A (en) 2000-10-03
CA2283464C (en) 2006-09-26
AU742175B2 (en) 2001-12-20
WO1998039031A1 (en) 1998-09-11
ZA981838B (en) 1999-02-19
JP2001515353A (ja) 2001-09-18
EP1005366A1 (en) 2000-06-07
JP4223068B2 (ja) 2009-02-12
US20030073080A1 (en) 2003-04-17
US6392028B1 (en) 2002-05-21
JP2008167755A (ja) 2008-07-24
IL131688A (en) 2007-09-20
US20020102540A1 (en) 2002-08-01
EP1005366A4 (en) 2004-05-19
AU6938698A (en) 1998-09-22
IL131688A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
JP4094679B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）用の機能性ｄｎａクローン及びその使用
EP0856051B1 (en) Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof
WO1998039031A9 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
US7935676B2 (en) Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2A, and a cell having such nucleic acid construct introduced therein
JP4095303B2 (ja) Ｈｃｖ変異体
US7407758B2 (en) HCV variants
US7235394B1 (en) Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7794942B2 (en) Cell lines permissive for HCV replication
US7338759B1 (en) HCV variants
US20040039187A1 (en) Chimeric GB virus B (GBV-B)
AU2006202902B2 (en) HCV variants
US20030028010A1 (en) Functional DNA clone for hepatitis C virus ( HCV) and uses thereof
AU2001263407A1 (en) Hcv variants
WO2007013882A9 (en) In vitro model for hepatitis c virion production
CA2483513A1 (en) Reporter-selectable hepatitis c virus replicon

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041001

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20051011

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20051012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061122

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20061122

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20071228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080306

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110314

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110314

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120314

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130314

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130314

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140314

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term